Table 5

Other dermatological events in patients with rheumatoid arthritis (RA) given TNF-α-blocking therapy

Patient no.

Age (yr)

Sex

Diagnosis

Druga

Active treatment

Event

Clinical description

Localization

Time to event

Biopsy

Comedicationb

Permanent withdrawal anti-TNF-α

Therapy

Course


1

56

f

RA

A

Yes

Lymphomatoid papulosis-like eruption

Macular erythematosquamous lesions

Lower arms, upper legs and trunk

2.6

Yes

naproxen

No

None

Recovery

2

53

f

RA

A

Yes

Rosacea

Diffuse erythema, scaling, telangiectasias

Head and face

1.9

Yes

prednisolone, captopril, indomethacin, midazolam

No

Topical

Persisting

3

74

f

RA

E

Yes

Pruritus

Itch

Trunk

2.5

No

None

No

Topical

Unknown

4

61

f

RA

I

No

Ecchymoses

Ecchymoses

Hands and feet

25.9

No

AZA, prednisolone

No

Topical

Partial recovery

5

58

f

RA

I

Yes

Drug-induced systemic lupus emythematosus

Discoid erythematous lesions, aphthous lesions, ANA positive, anti-ds-DNA positive

Hands, face, scalp

20.0

No

MTX

Yes

Topical and systemic

Recovery, no rechallenge

6

68

m

RA

I

Yes

Transient swelling of unknown cause

Transient swelling 2 × 3 cm

Scalp

20.0

No

MTX, folic acid, naproxen

No

None

Recovery

7

52

f

RA

L

Yes

Dermatomyositis

Livid erythema, raised CPK, decreased proximal muscular strength

Inner upper arms and legs

2.5

Yes

None

Yes

None

Recovery

8

53

m

RA

L

No

Erythema nodosum

Painful erythematous nodules

Lower legs

7.4

Yes

AZA, naproxen, paracetamol

No

Topical

Partial recovery


aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bMTX, methotrexate; AZA, azathioprine. CPK, creatinine phosphokinase; f, female, m, male.

Flendrie et al. Arthritis Research & Therapy 2005 7:R666-R676   doi:10.1186/ar1724

Open Data